Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal squamous cell carcinoma (ESCC) is a deadly disease for which no effective targeted therapeutic agent has been approved. Both AXL and c-MET have been reported to be independent prognostic factors for ESCC. Thus, inhibitors of AXL/c-MET might have great potential as targeted therapy for ESC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Pei-Wen, Liu, Yu-Cheng, Chang, Ya-Han, Lin, Ching-Ching, Huang, Pei-Ming, Hua, Kuo-Tai, Lee, Jang-Ming, Hsieh, Min-Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851194/
https://www.ncbi.nlm.nih.gov/pubmed/31781483
http://dx.doi.org/10.3389/fonc.2019.01138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851194/
https://www.ncbi.nlm.nih.gov/pubmed/31781483
http://dx.doi.org/10.3389/fonc.2019.01138

Ejemplares similares